TLR4 and tuberculosis: In this work, we have characterized the GLA-LSQ adjuvant formulation (which contains a synthetic TLR4 agonist plus QS-21 in a liposomal formulation; this is similar to AS01 which instead contains MPL and QS-21 in a liposomal formulation) for prophylactic TB vaccine efficacy in the mouse model.